Publications
Berberine Binds in Silico to Anti-cancer Drug Target Enzyme Phosphoinositide 3-Kinase (Human PI3 K) with Affinity Comparable to Known Inhibitors of the Enzyme

K.S.V. Prabhu Rathnam¹,² and C. Damaodara Reddy¹*

¹Sugen Life Sciences Pvt.Ltd. 4/86, S.V.Nagar Perumallapalli, Tirupathi – 517502, India
²S.V.University, Tirupathi – 517502, India

*Corresponding author email id: prabhuratnam65@gmail.com

Abstract

Phosphoinositide 3-kinase (PI3K) is an intracellular enzyme functioning as an inositol lipid kinase and is activated by several upstream growth factor receptors. PI3 K controls diverse cellular responses including but not limited to cell proliferation, survival, etc. Several recent reports have undoubtedly proved that PI3K is a druggable target and several research groups and pharmaceutical companies are developing inhibitors. In the present study, we present the results of Insilco docking analysis of a phytocompound Berberine and were compared with several known commercial PI3 K inhibitors. Our results show that Berberine docks efficiently with the active site of PI3 K and forms stable bonds with active site amino acid residues and essentially stalls enzyme activity. Our results also show that the bonding energies of these interactions are far more superior to the commercial PI3 K inhibitors and probably advocates as a probable PI3 K inhibitor.

Article Info

Accepted: xx May 2018
Available Online: xx June 2018

Keywords

Berberine PI3K, Breast cancer, Triple negative, Epirubicin.

Introduction

Triple-negative breast cancers are characterized by lack of expression of both estrogen receptor (ER) and progesterone receptor (PR), as well as absence of human epidermal growth factor 2 (HER2) up regulation and accounts to 10-17% of all breast carcinomas (Shoemaker et al.(2018)). TNBCs are associated with an overall poor prognosis as exemplified by a higher rate of early recurrence and distant metastasis to brain and lungs compared to other breast cancer subtypes. The treatment options for TNBCs are limited. Although, early TNBC can be sensitive to standard chemotherapy (anthracyclines, taxanes, ixabepilone, and platinum agents), traditional hormone therapies and targeted agents such as trastuzumab are not effective in this phenotype of cancer (Dent et al.(2007)). Recent studies have indicated that the accumulations of defects in cellular regulation mechanisms are underlying the cause for resistance to conventional chemotherapy accounting for 90% of drug failures in TNBC’s (Foulkes et al., (2010)). Therefore, to enhance treatment efficacy, targeted therapies to specific signaling molecules over-expressed and implicated in the pathogenesis of TNBCs holds promise in treatment.
Bioactive compounds from dietary phytochemicals are well studied for their chemopreventive and chemotherapeutic effects. Investigations of several bioactive compounds revealed their ability to function as multi-targeting agents to antagonize dysregulated targets in cellular signaling pathways to exert their anti-neoplastic activities (Saldanha et al. (2012)). Altering genes that affect these pathways can serve as suitable tools to decrease tumor mass and also allow for tumor regression. Various studies have shown that these molecules can induce apoptosis, inhibit cellular proliferation, affect angiogenesis, and affect cancer metabolism in various cancers, all of which are hindrances to tumor growth. Thus an effective nutraceutical is one that will have a low nontoxic dose to create the magnitude of death inducing changes in the tumor dynamics. Phytochemical modulate an array of signaling pathways, as well as individual molecular targets. Available literature reveals that natural anticancer agents have been shown to touch upon virtually every single molecular target (Sun et al. (2002)).

A few major signaling pathways/targets affected by nutraceutical or phytocompound that have been characterized include but not limited to: EGFR family of receptors, Ras/Raf signaling, PI3K/Akt/mTOR pathway, Notch family, Wnt/β-catenin signaling, MAPK/ERK pathway, among others (Torres et al, 2012 and Singh et al, 2011).

Berberine is a benzylisoquinoline alkaloid extracted from the roots, rhizomes, stem of several plants such as Berberis vulgaris-Barberry, Berberis aristata. Berberine has a molecular weight of 336.367 g/mol and the molecular formula is C20H18NO4. The hydrogen bond donor count is 0 and acceptor count is 4. It is a solid substance and has a melting point of 145°C. The XlogP value is 3.6. It is slowly soluble in water.

Berberine is used as potent anti-diabetic drug which decreases the blood glucose level by various mechanisms such as decreasing insulin resistance, decreasing gluconeogenesis and increasing glycolysis. The anticancer role of Berberine is gaining importance and few international groups are working on deciphering the mechanism of action (LMG Ortiz et al, 2014). It is on these lines, the present study was undertaken to show for the first time the molecular docking of Berberine with an important signaling node active in cancer cells, namely, Phosphatidyl inositol 3-kinases (PI3 K). It catalyses the transfer of terminal phosphate to the membrane bound lipid phosphatidyl inositol and triggers a signaling cascade resulting in activation of several downstream proteins involved in cell proliferation and differentiation (Fiona M. Foster et al, 2003). Several epithelial tumor types have been shown to have dysregulated PI3 K levels and have been directly implicated in malignant transformation process (J. E. Dancey, 2004).

Materials and Methods

Molecular docking

Molecular docking was carried out using MOE (Molecular Operating Environment) docking software tool (MOE 2011.10). The 3D structure of Berberine, Epirubicin, and known PI3-K inhibitors such as BKM-120, CH5132799, GDC-0941, GDC0980, GSK 2126458 and LYS294002 was retrieved from PubChem (ID 2353) and its geometry was optimized in MOE working environment. The protein PI3 kinase structure was loaded into MOE software removing water molecules, hetero atoms and polar hydrogens were added. The structures were protonated at a temperature of 300K, pH 7 and the salt concentration was kept at 0.1M. Generalized born implicit solvating environment was enabled with a dielectric constant of 1 and Vanderwaal’s forces were enabled at a cut off value of 10 Å. Energy minimization was carried out in OPLS (Optimize Potential for Liquid Simulations) force field at a gradient of 0.05 to calculate the atomic coordinates of the protein that are local minima of molecular energy function and also to determine low energy conformations and to proceed for molecular dynamics simulations. The simulations were carried out in the same force field and NVT statistical ensemble was used where the temperature is held fixed to generate the trajectories. The most accurate Nose-Poincare-Anderson algorithm was enabled to solve the equation of motion during simulations. The initial temperature was set at 30K and increased to a run time temperature of 300K and the simulations were carried out for a total period of 10 nano seconds and these stabilized conformations generated at the end of the simulations were used for molecular docking process.

Individual dockings were performed for protein PI3 kinase with Berberine, Epirubicin, BKM-120, CH5132799, GDC-0941, GDC0980, GSK 2126458 and LYS294002 to find out the binding modes and affinity variations. These poses were generated by superposition of ligand atom triplets and triplets of receptor site points using alpha triangle docking placement methodology. The docked conformers are ranked by London dG scoring function to estimate the free energy of binding of
the ligand from a given pose. The conformations thus were refined and rescored in the same force field to remove the duplicate conformations (Ahmed Jeri et al., (2015)). At the end of docking process the pose with least score was chosen from the total conformations and in each docking process the binding orientations of Berberine and Epirubicin was studied in the binding sites of protein PI3-K (J. E. Dance (2004)).

Results and Discussions

The interaction pattern of the phytocompound Berberine with the cellular protein target namely PI3 Kinase suggest an important role in execution of its pharmacological effects. Consistent with our in-vitro findings, we were able to see good protein – ligand interaction with the cellular target PI3 Kinase, involved in the mechanism of action of Berberine.

To substantiate the findings for the in vitro studies, docking studies were performed and the target protein selected was the intra cellular signaling kinase, Phosphatidyl inositide 3- Kinase (PI3-K). Docking was performed with the substrate binding site of the kinase and the docking energies, bond formation were all recorded. In the present study, Berberine and Epirubicin were tested in the in vitro studies, nevertheless, docking was carried out with 6 other additional small molecule compounds, listed as PI3-K inhibitors. The 6 small molecules listed as PI3 Kinase inhibitors were chosen from Pubchem, BKM-120, CH5132799, GDC-0941, GDC0980, GSK 2126458 and LYS294002. Results of this docking study show among all the compounds that were docked with PI3-K, Berberine showed very promising results with a docking score of -10.5966 kcal/mol, while the next best was Epirubicin, which had a score of -10.8622 kcal/mol. On comparison the docking scores for the other small molecules were not significant. The results of the molecular docking studies, in terms of bond formation, energy are summarized in Table. 1. The 2-D docking poses of Berberine with the substrate binding site of PI3-Kinase and the interacting amino acid residues are shown in Figure-1. The 3-D docking poses of Berberine and Epirubicin is shown in Figure 2. The 2-D and 3-D docking poses of the other 6 small molecules are shown in Figures- 3 and 4 respectively.

Table.1 In Silico Docking scores of Berberine, Epirubicin and Selective Inhibitors with PI3Kinase

| S. No. | Drug      | Target  | Docking score | No. of H-Bonds | Interacting residues | H-bond length(Å) |
|--------|-----------|---------|---------------|----------------|----------------------|------------------|
| 1      | Berberine | PI3 kinase | -10.5966     | 4              | Ser50                | 2.3              |
|        |           |         |               |                | Ser50                | 2.5              |
|        |           |         |               |                | Lys71                | 2.8              |
|        |           |         |               |                | Ala49                | 3.0              |
| 2      | Epirubicin | PI3 kinase | -10.8622     | 3              | Lys63                | 3.0              |
|        |           |         |               |                | Asp41                | 2.4              |
|        |           |         |               |                | Asp41                | 2.6              |
| 3      | BKM-120   | PI3 kinase | -10.1743     | -              | -                    | -                |
| 4      | CH5132799 | PI3 kinase | -9.8694      | 1              | Arg47                | 2.7              |
| 5      | GDC-0941  | PI3 kinase | -10.4513     | 1              | Asn33                | 2.2              |
| 6      | GDC0980   | PI3 kinase | -10.5462     | 2              | Asn67                | 2.5              |
|        |           |         |               |                | Asn67                | 2.8              |
| 7      | GSK 2126458 | PI3 kinase | -10.0443    | -              | -                    | -                |
| 8      | LYS294002 | PI3 kinase | -9.6507      | -              | -                    | -                |
Figure 1 *In Silico* Docking of Berberine, Epirubicin - 2D Images of Docking with target PI3 Kinase

Figure 2 *In Silico* Docking of Berberine, Epirubicin - 3D Images of Docking with target PI3 Kinase
Figure 3 *In Silico* Docking of Selective Small molecules - 2D Images of Docking with target PI3 Kinase

![Figure 3](image)

Figure 4 *In Silico* Docking of Selective Small Molecule Inhibitors - 3D Images of Docking with target PI3 Kinase

![Figure 4](image)
Further in depth analysis of the docking study for Berberine with the target kinase PI3-K showed that it interacts with important amino acid residues namely, Ser50, Ser 50, Lys71 and Ala 49 forming a total of four hydrogen bonds. The N-2 atom of the compound berberine formed a strong hydrogen bond interaction with the NH group of Ser50 and the distance was computed to be 2.3 Å. Furthermore, the N-2 atom of the compound berberine formed a strong hydrogen bond interaction with the NH group of Lys71 (distance=2.5 Å). Finally, the N-2 atom of the compound berberine formed a strong hydrogen bond interaction with the with the NH group of Ala49 (distance=3.0 Å).

Molecular docking studies of the substrate binding site of PI3-Kinase with Epirubicin revealed that it interacts with Lys63 and Asp41 forming a total of three hydrogen bonds. The N-2 atom of the compound epirubicin formed a strong hydrogen bond interaction with the with the NH group of Lys63 (distance=3.0 Å) and the N-2 group of epirubicin formed a strong hydrogen bond interaction with the NH group of Asp41. The 2-D docking poses of Berberine and Epirubicin with the substrate binding site of PI3-Kinase and the interacting amino acid residues are shown in Figure-1.

Overall, the docking studies show that Berberine can efficiently interact with the substrate binding site of PI3-Kinase and probably may influence the activity of the enzyme and thereby may influence the downstream signalling in breast cancer cells. The in silico data is in alignment with the in vitro studies and essentially corroborates the effective anti cancer activity of Berberine and Epirubicin alone and in combination on breast cancer cells.

References

Ahmed Jeri, Yahiya Hoban, B Vend Kumar, and Anil Biwa. Curcumin binds in silico to anti-cancer drug target enzyme MMP-3 (human stromelysin-1) with affinity comparable to two known inhibitors of the enzyme. Misinformation. 2015; 11(8) 387–392.

Dent R, Trudeau M, Pritchard KI, Hanna WM, Kahn HK, Sawka CA, Lickley LA, Rawlinson E, Sun P, Narod SA. Triple-negative breast cancer: clinical features and patterns of recurrence. Clin Cancer Res. 2007 Aug 1;13(15 Pt 1):4429-34.

Fiona M. Foster, Colin J. Traer, Siemon M. Abraham, Michael J. Fry. The Phosphoinositide (PI) 3-kinase family. Journal of Cell Science 2003. 116: 3037-3040.

Foulkes WD, Smith IE, Reis-Filho JS. Triple-negative breast cancer. N Engl J Med. 2010 Nov 11; 363(20):1938-48.

J. E. Dance. Molecular targeting: PI3 kinase pathway. Annals of Oncology2004, 15 (Supplement 4): iv233 – iv239.

LMG Ortiz, P Lombardi, M Tillhon, Al Scovazzi (2014) Berberine: an epiphany against cancer. Molecules. 19(8), 12349-12367.

URL:https://pubchem.ncbi.nlm.nih.gov/compound/Berberine: an epiphany against cancer. Molecules. 19(8), 12349-12367.

Singh T, Vaid M, Katiyar N, Sharma S, Katiyar SK. Berberine, an isoquinoline alkaloid, inhibits melanoma cancer cell migration by reducing the expressions of cyclooxygenase-2, prostaglandin E₂ and prostaglandin E₂ receptors. Carcinogenesis. 2011 Jan; 32(1):86-92.

Sun, J.; Chu, Y.-F.; Wu, X.; Liu, R. H. (2002). Antioxidant and antiproliferative activities of common fruits. J. Agric. Food Chem, 50, 7449-7454.

Torres et al. 2012 Torres MP, Rachagani S, Purohit V, Pandey P, Joshi S, Moore ED, Johansson SL, Singh PK, Ganti AK, Batra SK. Graviola: a novel promising natural-derived drug that inhibits tumorogenicity and metastasis of pancreatic cancer cells in vitro and in vivo through altering cell metabolism. Cancer letters. 2012 Oct 1; 323(1):29-40.

How to cite this article:

Prabhu Rathnam, K.S.V. and Damaodara Reddy, C. 2018. Berberine Binds in Silico to Anti-cancer Drug Target Enzyme Phosphoinositide 3- Kinase (Human PI3 K) with Affinity Comparable to Known Inhibitors of the Enzyme. Int.J.Curr.Res.Aca.Rev. 6(6), xx-xx. doi: https://doi.org/10.20546/iijcrar.2018.606.xxx
In-\textit{vitro} Anticancer Activity of Berberine alone and in Combination with Epirubicin on Breast Cancer Cells

K.S.V. Prabhu Rathnam$^{1,2}$ and C. Damodara Reddy$^1$*

$^1$Sugen Life Sciences Pvt.Ltd. 4/86, S.V.Nagar Perumallapalli, Tirupathi – 517502, India  
$^2$S.V.University, Tirupathi – 517502, India

*Corresponding author email id: cdr@sugenlife.com

Abstract

Herbal medicine is a major form of treatment for more than 70\% of the world's population. At present the use of patented herbal remedies comprised of dried and powdered whole herbs or herbal extracts, besides in tablet form. The study of natural products is multidisciplinary and involves several branches of biological sciences and medicine also. Natural products remain an important source of new structures, and are at the intersection of many fields. Though they may not be the final drug entity, but definitely provides a clue for the desired biological activity. Among several natural or herbal products available, Berberine, a well-known phyto compound has been chosen in the present study to decipher its mechanism of action on breast cancer alone and in combination with Epirubicin. Among the cancer types known to affect, breast cancers are common and in our country, and it’s been diagnosed in younger age patients with a poor prognosis. Thus the present study was devised to focus on the anti-cancer potential of Berberine alone and in combination with Epirubicin as a new therapeutic entity in the arena. The study was designed using comprehensive cellular and biochemical tools on two different human breast cancer cells namely MCF-7 & MDA MB 231 and also involved \textit{in-silico} docking methods. The study results have shown great promise in terms of deciphering the mechanism of action of Berberine alone and in combination with Epirubicin on breast cancer cells. MCF-7 & MDA MB 231 cells after treatment with Berberine and Epirubicin showed features of apoptosis and also inhibited cell migration. Berberine also showed synergistic chemotherapeutic effect when used in combination with Epirubicin on MCF-7 & MDA MB 231 cells. The present study provides conclusive evidence for future pre-clinical evaluation of Berberine alone and in combination with Epirubicin befitting and upcoming breast cancer chemotherapeutic agent.

Introduction

Natural products offer the best remedies for different disease condition since ancient times. They essentially provide clues for new drug development for several ailments including cancer, diabetes (Torres \textit{et al.}, (2012)). Cancers are categorised as chronic diseases and several types have been attributed to life style changes. These include high fat diet, smoking, prolific use of oral contraceptives among several others. Female breast cancer, has presently been stated to be top ranked among Indian population (Malvia \textit{et al.}, (2017)). Recent
statistical prediction for the year 2020 for Female breast cancer is 17, 97,900 and will significantly impact health budget (Allemani et al., (2018)). Another concern is that the female breast cancers have been diagnosed in younger population and these patients have poor prognosis, in terms of aggressive disease and drug resistant phenotype. In a recently published study in acclaimed journal The Lancet, termed as the CONCORD study, the scenario in India is alarming since the survival rates of breast cancer is poor when compared to several countries. It is in this juncture that the present work was initiated to find new natural product based compounds for effective chemotherapy of breast cancers. A major advantage of natural products based drugs/ compounds, is their excellent safety profile. Based on these premises we hypothesized that Berberine a well-known phyto compound present in several berries and a major constituent in Berberis species may have potent effect on breast cancer cells (Tong et al., (2012)). Present day chemotherapy regimen for breast cancer involve usage of cytotoxic agents which lack tumour cell specificity and hence kill normal cells, resulting in debilitating side effects. With this aspect in mind, we have chosen a well known cancer chemotherapy drug Epirubicin and have studied its anti cancer effects in combination with Berberine. In the present study, we have performed a series of cell biology based assays and determined levels of sensitive molecular markers to ascertain the molecular basis of drug action of Berberine on two well established breast cancer cell lines. In addition to single agent anti-cancer effect of Berberine, the present study has also determined the mechanism of action of combination chemotherapy of Berberine and Epirubicin and proposes a synergistic mechanism of action, for these two agents on the tested breast cancer cells.

**Materials and Methods**

**Cell lines and reagents**

MCF-7 and MDA MB 231 cells were obtained from National Centre for Cell Science, Pune, India. MDA MB 231 & MCF-7 cells were maintained in DMEM high glucose medium supplemented with 10% Fetal bovine serum (FBS), 100 units/mL Penicillin, and 100 μg/mL Streptomycin in an atmosphere of 95% air and 5% CO2 at 37°C.

Berberine (1065210-50MG) and Epirubicin (E9406-5MG) were obtained from Sigma-Aldrich. USA. FBS, DMEM, PEN/STREP were purchased from Invitrogen USA. MTT reagent was obtained from SRL; Primary antibodies: mTOR Rabbit mAb (2983- CST), PI3 Kinase p110α Ab (4255-CST), Bcl2 Ab (2872-CST), BAX Ab (2774-CST), BID Ab (2002-CST), Caspase 3 Ab (ab13586), Caspase 9 Ab (ab32539) and β-actin (A5441); Secondary antibodies conjugated with HRP were purchased from Santa Cruz (TX, USA); Primers were ordered from Sigma-Aldrich (FH1_BAX, FH1_Bcl2, FH1_CASP3 and FH1_CASP9). All Western-blot related chemicals were purchased from BIO-RAD (CA, USA), Merck (USA); Protease and Phosphatase inhibitors were purchased from Roche (USA). Nitrocellulose membrane for western blot and nylon membrane for EMSA purchased from Amersham. ECL was purchased from BIO-RAD; Trizol (RNAiso plus), cDNA synthesis kit and SYBR green mix were purchased from Takara (Japan). All reagents and chemicals used were of analytical grade.

**Cell viability assay**

To ascertain and quantify the cytotoxic activity of Berberine and Epirubicin on breast cancer cells, we performed the 3-(4, 5-dimethylthiazol-2-yl)-2, 5-diphenyltetrazolium bromide (MTT) assay, as described previously (Rafehi et al., (2011)).

Briefly, 5000 cells per well (MDA MB-231 & MCF-7) were plated in 96-well culture plates. After overnight incubation, the cells were treated with varying concentrations of Berberine (20,40,60, 80,100,150,200 and 300µM) & Epirubicin (1, 50, 100, 500 nM and 3, 5, 10 µM) for 24, 48, and 72 hours with three replicates. Absorbance was recorded at 540 nm with a reference at 650 nm serving as the blank. The effect of Berberine on breast cancer cell viability was assessed as percent cell viability compared with vehicle-treated control cells, which were subjectively assigned 100% viability.

**Clonogenic assay**

Equal number of cells were seeded on 65mm tissue culture dishes and incubated overnight at 37°C in a humidified atmosphere containing 5% CO2 for cell attachment. Cells were drug treated for 24h.

Untreated control, positive control and vehicle control were maintained simultaneously. Media change was done periodically. Colonies were fixed, stained and counted [Ahmadiankia et al., (2016)]. Plating efficiency and survival fraction was calculated and represented graphically.
Plating Efficiency (%) = \frac{\text{No. of colonies counted}}{\text{No. of cells seeded}} \times 100

Survival Fraction = \frac{\text{No. of colonies counted}}{\text{No. of cells seeded}} \times \text{PE of Control}

**Cell migration assay**

1.5x10^5 cells were seeded on 6 well plates and incubated overnight at 37°C in a humidified atmosphere containing 5% CO₂ for cell attachment. Following treatment with mitomycin-C scratch was induced and cells were drug treated and monitored at 0h and 24h (Chou et al., 2006)). Percentage of migration was calculated and represented graphically.

\[
\text{Percentage of migration} = \frac{\text{Width at 0h} - \text{Width at 24h}}{\text{Width at 0h}} \times 100
\]

**Combination therapy experiments**

For drug combination experiments (5), cells were treated under 3 different configurations, namely:

- Co treatment with Berberine and Epirubicin for 48h
- Pre treatment with Berberine for 12h followed by Epirubicin for 48h
- Pre treatment with Epirubicin for 12h followed by Berberine for 48h

Subsequent to the treatments, the plates were processed for MTT assay as described earlier.

**Quantification of gene expression by Real Time PCR**

Cells (1 x 10^6) were seeded in 100mm plates and allowed to attach overnight. Next, cells were treated with Berberine and Epirubicin for 24h.Total RNA was isolated from untreated and treated cells using Trizol reagent. The yield and purity of isolated RNA was checked by UV spectrophotometry. 2 μg of total RNA were used in reverse transcription reactions using the C-DNA reverse transcriptase kit according to manufacturer’s protocol. Gene expression in untreated and treated cells were determined by real-time PCR using the reverse transcription product, gene-specific primers (5 pmol) and SYBR green in a 20 μL reaction volume on the 7500 Fast RT PCR machine (ABI, Carlsbad, CA). Relative changes in mRNA expression levels of genes involved in apoptosis (8) were assessed by the \(2^{-\Delta\Delta CT}\) method and changes in mRNA expression of the target gene were normalized to that of GAPDH gene.

Real-time PCR cycle parameters included 10 min at 95 °C followed by 40 cycles involving denaturation at 95 °C for 15 s, annealing at 60 °C for 20 s and elongation at 72 °C for 20 s. The oligonucleotides used as specific primers (Table 1) for each gene were as follows:

**Determination of Apoptotic Protein expression by Immunoblotting**

MDA MB 231 & MCF-7 cells (1 x 10^6) were seeded in 100mm plates and allowed to attach and grow. Upon 80% confluence of cells were treated with Berberine and Epirubicin. For whole cell protein, lysates were collected using RIPA buffer containing protease/ phosphatase inhibitor cocktail. For nuclear protein, first cytoplasmic extract was collected using buffer A (1M HEPES pH 7.9, 2M KCl,0.5M EDTA pH 8, 0.1M EGTA pH 7, 0.1M DTT, 10% NP40, protease inhibitor) and later nuclear protein extract were collected using buffer B (1M HEPES pH 7.9, 5M NaCl,0.5M EDTA pH 8, 0.1M EGTA pH 7, 0.1M DTT and protease inhibitor). The protein concentrations were measured spectrophotometrically using Bio-Rad protein assay kit. Equivalent amounts (100μg) of protein lysates were separated by electrophoresis in 12 % SDS polyacrylamide gel and blotted onto nitrocellulose membrane. The blotted membranes were incubated with primary antibodies for proteins involved in apoptosis pathways. (American cancer society,2011)

The data were analyzed by CompuSyn software with the results showed in combination index (CI) values, where CI value <1, =1, and >1 refer to synergetic, additive, and antagonistic effects, respectively [Balakrishna et al., (2015) & Patil et al., (2010)].
The proteins were visualized using an ECL kit and image acquisition and analysis was performed using Bio Rad Versadoc system.

**Statistical analyses**

All experiments were performed using suitable replicates and were repeated three times. IC50 was calculated using Graphpad Prism 6 (GraphPad Software, San Diego, CA) using the observed cell viability values and SEM. For the combination therapy experiments CompuSyn software program was used.

For determining the combination index (CI) for the combination therapy experiments, data is represented as Fa (Fraction affected). Fa is obtained by calculating the % viability and subtracting from 100. The obtained value is divided by 100 to obtain the fraction. Based on the values obtained from the computational analysis, the effects of the drugs used in combination (Berberine & Epirubicin) is categorised as Synergistic, Additive or Antagonistic effect.

**Results and Discussions**

**Berberine preferentially inhibits breast cancer cell proliferation**

The effect of Berberine on MDA MB 231 & MCF-7 cell morphology were evaluated. Phase contrast imaging (Figure 1 & 2 respectively) showed that untreated control MDA MB 231 & MCF-7 cells were epithelial-like adherent cells, with a flat and polygonal shape, that grew homogeneously and showed strong refraction.

When treated with Berberine at 24h, 48h & 72h, the cells showed reduced refraction and shrunk to a round shape. The treated cells grew in a scattered way, resulting in loss of intercellular adhesion. The microscope images also showed lot of floating dead cell and debris indicating cytotoxic effect.

**Epirubicin treatment induced morphological changes on breast cancer cells**

Epirubicin, a well-known anti-cancer agent, was used in the study and experiments carried out in tandem as above showed that treated MDA MB 231 and MCF-7 cells (Figure 3 & 4 respectively) had reduced refraction and shrunk to a round shape, indicating cell death initiation. Epirubicin was extremely cytotoxic at very low nanomolar concentrations.

**Berberine inhibited growth of breast cancer cell lines**

To determine the effect of Berberine on the proliferation of BR Cancer cell lines two human cell lines, MDA MB 231 and MCF-7, were treated with varying concentrations of Berberine for 24, 48 and 72 h and the viable cells were quantitated using the MTT assay. As shown in Figure 1 & 2, Berberine inhibited growth of all cell lines in a dose and time-dependent manner. Berberine, however, was more effective in suppressing proliferation of the MDA MB 231 than MCF-7 cells. The IC50s of Berberine for MDA MB 231 at 48 and 72 h were 21.54 and 10.42 µM and those for MCF-7 were 187.9 and 163.1 µM. (Table 2). Consistent with the cell morphology data as recorded by phase contrast imaging (Figure 1 & 2) showed that Berberine suppressed proliferation and probably triggered cell death pathways and has been aptly confirmed and quantified by the MTT assay.

**Epirubicin inhibited growth of breast cancer cell lines**

Epirubicin treatment of the breast cancer cells showed a dose and time dependent cell death and the IC50 of Epirubicin for MDA MB 231 at 48 and 72 h were 676.6 and 47.53 Nm (Supplementary Figure 3) and those for MCF-7 were 85.2 and 7.69 Nm (Supplementary Figure 4). The MTT data (Table 2) were found to be aligned with the cell morphology recording confirming the cytotoxic effect of Epirubicin.

**Effect of Berberine on cell survival**

The most important assay for assessing the anti cancer activity of any drug is the In vitro clonogenic assay. This assay essentially determines the ability or capacity of the cells to divide and produce progenies, i.e. a single cell to form a colony comprising of about 50 cells or more. Drug treated cells are compared with vehicle control treated cells to show the difference in the number of colonies formed and thereby making it feasible to quantify the ability of drugs to inhibit the cell division process.

Treatment of Breast cancer cells MDA MB 231 & MCF-7 cells with various concentrations of Berberine resulted in a concentration dependent decline in the clonogenicity of cells. Results showed a continuous decline in the cell survival with a lowest survival of 8.86% for 90 µM for MCF-7 (Figure 4 & 5). Whereas for MDA MB 231, a lowest survival of 19.10% for 20 µM was determined (Figure 5, Table 3). Thus the reproductive capability of
MDA MB 231 & MCF-7 cells decreased significantly with increase in concentration of Berberine. This was quantified by calculating the plating efficiency and survival fraction. Plating efficiency of MDA MB 231 & MCF-7 cells declined as drug concentration increased.

**Effect of Epirubicin on cell survival**

Treatment of the breast cancer cells showed a lowest survival of 2.58% for 40 Nm of Epirubicin for MCF-7 cells and 13.3% for 300Nm of Epirubicin for MDA MB 231 cells. (Figure 4 & 5). Thus the reproductive capability of MDA MB 231 & MCF-7 cells decreased significantly with increase in concentration of Epirubicin. This was quantified by calculating the plating efficiency and survival fraction. Plating efficiency of MDA MB 231 & MCF-7 cells declined as drug concentration increased.

**Effect of combination of Berberine and Epirubicin on cell survival**

Concurrent treatment of Berberine and Epirubicin on MDA MB 231 & MCF-7 cells showed good inhibition of the reproductive potential. The least survival for MCF-7 cells was found at combination concentrations of Berberine 45µm and Epirubicin 20nm. Whereas, for MDA MB 231 the least survival fraction of 11.8% was found at a concentration of Berberine 20µm and Epirubicin 300nm. The clonogenic assay results summarized in Table 4C & 5B confirms that combination of Berberine and Epirubicin is more effective in killing breast cancer cells. Another noted inference from this result is that the concentration of Epirubicin required to effective cell kill is also reduced, thereby the side effects of Epirubicin therapy may also reduce considerably.

**Berberine reduced wound-healing migration of breast cancer cells**

The *in-vitro* wound healing assay or scratch assay is a simple and cost effective method to screen for compounds which can inhibit migration of cancer cells. This microscopic method essentially observes the closing of the wound or gap created on the cell monolayer and using microscope image analysis software the width or the gap can be measured, thereby giving a quantitative impact for the process of migration. This assay essentially measures the anti metastatic potential of Berberine alone and in combination with Epirubicin on MDA MB 231 and MCF-7 cells.

To confirm this inhibition of cell migration effect, we also performed the wound healing assay on MCF-7 cells and obtained serial images (Figure 6B) as well as quantified the migration areas. In MCF-7 cells on treatment with 90 µm of Berberine showed only 23.4% migration at the end of 6h treatment. While Epirubicin treated cell monolayer showed a migration rate of 29.6% at a concentration of 40nM. On closer examination of the gap or the wound on the MCF-7 cell monolayer treated with Berberine alone and in combination with Epirubicin, revealed that cells formed micro spike like structures on the surface and in the cell surface indicating formation of stress fibres and essentially signifying actin cytoskeleton remodelling. Whereas in the vehicle treated cell monolayer, these changes were not visible. The quantitative results of the wound healing assay on MDA MB 231 cells are summarized in Table 3A.

The inhibitory effect on cell migration was more potent on combination treatment. Berberine 90µm & Epirubicin 40Nm combination treated MCF-7 cells showed only 6.5% migration at the end of 6h as compared to the vehicle control, which showed 26.47%. Breast cancer cells after treatment with the drugs essentially showed cytoskeleton remodelling and altered plasma membrane contours and combination treatments of Berberine and Epirubicin was very effective in inhibiting cell migration, important in the process of cancer metastasis. Thus Berberine and Epirubicin combinations can possibly inhibit breast cancer metastasis. The
quantitative results of the wound healing assay on MCF-7 cells are summarized in Table 3B.

Overall, wound healing assay performed on MCF-7 and MDA MB 231 cells have shown that Berberine & Epirubicin combination has good effects on inhibiting cell migration.

**Co-treatment of Berberine and Epirubicin exerts synergistic cytotoxicity against MDA MB 231 triple negative breast cancer cells**

To determine the potential chemo preventive activity of Berberine and Epirubicin in combinations, we performed 3 different combination therapy experiments.

In the first set of assay, Co- treated MDA MB 231 cells with constant concentrations of Berberine (31.5μm) and increasing concentrations of Epirubicin (175 to 875 Nm) for 48h. At the end of the specified time point MTT assay was performed as mentioned earlier. The results showed Synergistic effect with a CI of 0.47 for a combination of Berberine 31.5μm and Epirubicin 875 Nm. Further the data showed with increasing concentrations of Epirubicin, the declined from 0.95 for Berberine 31.5μm and Epirubicin 175 Nm to the best result of 0.47 for Berberine 31.5μm and Epirubicin 875 Nm in a dose dependent manner. In the entire range of concentrations tested, data calculated as combination index (CI) showed only Synergism, which is a novel finding for the study. The results of the assay are summarized in Table 4A.

In the next set of combination therapy assay, we pre-treated MDA MB 231 cells with Berberine at a constant concentration of 31.5μm for 12h and then treated with 2 different concentrations of Epirubicin 175Nm & 875 Nm for 48h. The results showed Synergism at the concentrations tested. The CI of 0.27 was obtained for a combination of Berberine 31.5μm and Epirubicin 875 Nm. This pre-treatment of Berberine assay essentially exemplifies the fact that Berberine sensitizes the cells to Epirubicin and the CI value of 0.27 obtained on pre treatment is lower than the co treatment value of 0.47. The results of the assay are summarized in Table 4B.

In another combination therapy experiment module, we pre-treated MDA MB 231 cells with 3 different concentrations of Epirubicin 175Nm, 350Nm & 875 Nm for 12h and then treated with Berberine at a constant concentration of 31.5μm for 48h. The results showed Synergism at the concentrations tested. The CI of 0.38 was obtained for a combination of Epirubicin 175 Nm & Berberine 31.5μm. The results of the assay are summarized in Table 4C.

It is important to note that in all the above combination therapy experiments the CI value were less than one, suggesting that the growth inhibitory effect of these compounds namely Epirubicin & Berberine in combination was synergistic rather than additive or antagonistic.

**Co-treatment of Berberine and Epirubicin exerts synergistic cytotoxicity against MCF-7 breast cancer cells**

To establish whether the anti-tumor action of Berberine and Epirubicin in MCF-7 human breast cancer cells were synergistic, additive or antagonistic, the growth inhibitory effects were analysed after MTT assay. Results indicate that at a constant concentration of Berberine (235μm) and increasing concentrations of Epirubicin (43 to 106 Nm) for 48h. The results showed Synergistic effect with a best CI of 0.13 for a combination of Berberine 235μm and Epirubicin 106 Nm. The results of the assay are summarized in Table 5A.

In the next set of combination therapy experiment, we pre-treated MCF-7 cells with 2 different concentrations of Epirubicin 21Nm, 43Nm for 12h and then treated with Berberine at a constant concentration of 47μm for 48h. The results showed Synergism at the concentrations tested. The CI of 0.74 was obtained for a combination of Epirubicin 43 Nm & Berberine 47μm. The results of the assay are summarized in Table 5B.

In summary, the combination therapy experiments carried out on two different breast cancer cell lines, namely MDA MB 231 and MCF-7 conclusively suggested a Synergistic effect of Berberine and Epirubicin. This data has laid the basis for pre clinical evaluation of Berberine and Epirubicin combination in breast cancer tumour models and probably propose the same combination in future human clinical trials subsequently.

**Quantitative PCR Analysis for important apoptotic markers**

Breast carcinogenesis is a multi step process involving several molecular players and in particular growth factor receptor signalling regulating cell death pathways are
prominently implicated. In this regard, to examine the status of the intracellular signalling molecules responsible for the apoptotic activity in MDA MB 231 & MCF-7 cells, mRNA expression levels of apoptotic markers (BAX, BCL-2, Caspase-3 and Caspase-9) were studied by real-time RT PCR following exposure to Berberine for 24h. Caspase 3 & 9 are proteases playing a crucial role in triggering apoptosis and quantifying the gene expression after drug treatment throws light on the cellular death machinery. Similarly, BCL-2 & BAX important players in apoptotic signalling were also measured. (Figure 7 & 8).

To quantify the levels of selective genes involved in induction of apoptosis, MDA MB231 cells were treated with Berberine (52.3 μm), 826.7 Nm Epirubicin, alone and in combination. MDA MB 231 cells treated with Vehicle control were used as controls for comparison. Results showed that the mRNA levels of the tested panel of apoptotic markers namely BAX, BCL-2, Caspase-3 and Caspase-9 were significantly altered in MDA MB 231 & MCF-7 cells upon treatment with Berberine & Epirubicin alone and in combination. The effect showed changes in levels of expression in treated cells, indicating a trigger of apoptosis.

To quantify the levels of selective genes involved in induction of apoptosis on MCF-7 cells were treated with Berberine (200 μm), 113 Nm Epirubicin, alone and in combination. MCF-7 cells treated with Vehicle control were used as controls for comparison. The results showed significant changes in levels of expression of Bcl-2, indicating a trigger of apoptosis cascade.

**Immunoblot analysis for selected apoptosis markers**

Further to gain a deeper insight into the mechanistic pathway of apoptosis induced by Berberine alone and in combination with Epirubicin, we next tested the protein levels of BAX, BCL-2, BID, Caspase-3 & Caspase-9 following treatment. MDA MB 231 and MCF-7 cells after treatment with Berberine (IC50) and Epirubicin alone and in combinations, were lysed, proteins quantified and separated in SDS PAGE. They were immunoblotted using corresponding Abs and visualized.

MDA MB 231 & MCF-7 cells treated with Berberine alone and in combination with Epirubicin showed caspase 9 activation, the apical caspase involved in the intrinsic pathway of apoptosis. As shown in (Figure 9), when MDA MB 231 cells were treated with Berberine alone and in combination with Epirubicin, procaspase-9 with a molecular weight of 50 kDa was converted to an active form of caspase-9 with a molecular weight of 37 kDa, indicative of apoptosis activation.

Together, these results strongly delineate that Berberine alone and in combination with Epirubicin induced apoptosis is mediated through the intrinsic/mitochondrial-mediated pathway by activation of Caspases.

Further we also showed deregulated expression of PI3 Kinase and mTOR. PI3-Kinase and mTOR are important intra cellular signalling nodes in growth factor receptor signalling, which are active in breast cancer cells. The difference in levels of these 2 proteins in breast cancer cells MDA MB 231 & MCF-7, as shown by immune blot analysis provides evidence for alteration in growth factor receptor signalling upon treatment with Berberine and Epirubicin. Actin was used as the loading control to show uniform protein loading in the immunoblot. The results of the Immunoblot analysis are shown in Figure 9. Results show altered protein levels of the apoptotic proteins BAX, BCL-2, BID, Caspase-3 & Caspase-9, indicating apoptosis is being triggered.

| S. No | Name     | Forward Primer                  | Reverse Primer                  |
|-------|----------|---------------------------------|---------------------------------|
| 1.    | BAX      | 5'-TGCTTCAGGGTTTTCATCCAG-3’     | 5’-GCCGGCAATCATCCTCTG-3’        |
| 2.    | BCL2     | 5’-AGGAAGTGAACATTTCGGTGAC-3’    | 5’ GCTCAGTTCCAGGACCAGGC 3’      |
| 3.    | Caspase 3| 5’-ACATGGGCGTGTCAATAAATACC-3’  | 5’-CACAAAGCGACTGGATGAAC-3’      |
| 4.    | Caspase 9| 5’-CCAGAGATTCCGAACCAGAGG-3’    | 5’-GAGCACCGACATCACAAATCC-3’     |
Table 2: IC50 Values for Berberine & Epirubicin on MCF-7 & MDA MB 231 cells computed using GraphPad software

| Drugs   | Time | MDA MB 231 | R²  | MCF-7  | R²  |
|---------|------|------------|-----|--------|-----|
| BBR (μM)| 24   | 52.33      | 0.8868 | 200    | 0.87 |
|         | 48   | 21.54      | 0.9227 | 187.9  | 0.95 |
|         | 72   | 10.42      | 0.8739 | 163.1  | 0.95 |
| EPI (nM)| 24   | 826.7      | 0.9117 | 1130   | 0.97 |
|         | 48   | 676.6      | 0.8828 | 85.2   | 0.94 |
|         | 72   | 47.53      | 0.8296 | 7.69   | 0.88 |

Table 3A & B: Berberine alone & in Combination with Epirubicin inhibits cell migration in MDA MB 231 & MCF-7 cells

Table 5A & B: *In-Vitro* Combination Therapy on MCF-7 cells—with Berberine & Epirubicin. A. Simultaneous treatment of Epirubicin & Berberine (48h). B. Pre treatment with Epirubicin (12h) followed by treatment with Berberine (48h)
Table 4 *In Vitro* Combination Therapy on MDA MB 231 cells – with Berberine & Epirubicin. A. Simultaneous treatment of Epirubicin & Berberine (48h). B. Pre treatment of Berberine (12h) followed by treatment with Epirubicin (48h). C. Pre treatment with Epirubicin (12h) followed by treatment with Berberine (48h)

| Simultaneous treatment (48h) of Epirubicin and Berberine on MDA MB-231 cell line |
|-----------------------------------------|-----------------|-----------------|-----------------|-----------------|
| Epirubicin [nM] | Berberine [μM] | Fraction affected [Fₐ] | CI | CI effect |
|-----------------|----------------|--------------------------|----|-----------|
| 175             | 31.5           | 0.494                    | 0.95772 | Synergism |
| 350             | 31.5           | 0.55                     | 0.88225 | Synergism |
| 700             | 31.5           | 0.64                     | 0.69833 | Synergism |

| Pre treatment with Berberine (12h) followed by treatment with Epirubicin (48h) on MDA MB-231 cell line |
|-----------------------------------------|-----------------|-----------------|-----------------|-----------------|
| Epirubicin [nM] | Berberine [μM] | Fraction affected [Fₐ] | CI | CI effect |
|-----------------|----------------|--------------------------|----|-----------|
| 175             | 31.5           | 0.5                      | 0.72588 | Synergism |
| 875             | 31.5           | 0.8                      | 0.27922 | Synergism |

| Pre treatment with Epirubicin (12h) followed by treatment with Berberine (48h) on MDA MB-231 cell line |
|-----------------------------------------|-----------------|-----------------|-----------------|-----------------|
| Epirubicin [nM] | Berberine [μM] | Fraction affected [Fₐ] | CI | CI effect |
|-----------------|----------------|--------------------------|----|-----------|
| 175             | 31.5           | 0.64                     | 0.38318 | Synergism |
| 350             | 31.5           | 0.58                     | 0.6609  | Synergism |
| 875             | 31.5           | 0.68                     | 0.6482  | Synergism |
Figure 1 Growth inhibitory effects of Berberine (BBR) in MDA MB 231 breast cancer cells when compared with vehicle control. Representative micrographs from random fields of view (magnification 20X) of indicated cells treated with and without Berberine.
Figure 2 Growth inhibitory effects of Berberine (BBR) in MCF-7 breast cancer cells when compared with vehicle control. Representative micrographs from random fields of view (magnification 20X) of indicated cells treated with and without Berberine.
Figure 3 Anti-proliferative effects of Berberine on A. MDA MB 231 & B. MCF-7 breast cancer cells. Berberine Preferentially Inhibits Breast Cancer Cell Proliferation

The anti-proliferative effects were determined by the MTT assay. These results are presented as percentage of live cells as against log scale of molar concentrations.
**Figure 4** Clonogenic Assay on MCF-7 breast cancer cells after BBR & EPI treatment alone & in Combination. Berberine at different concentrations inhibits clonogenicity of MCF-7 cells as determined by clonogenic cell survival assay. A. Quantitative representation of reduction in number of colonies with representative images. B. Graphical representation for Inhibition of reproductive potential of MCF-7 cells after treatment as determined by Clonogenic assay. C. Tabulation of the % Survival after treatment with Berberine & Epirubicin alone and in combination. P.E: Plating Efficiency; % S: Percentage Survival

A.

![Clonogenic Cell Survival Assay](image)

B.

### Clonogenic Cell Survival Assay

| Condition                | % Survival 2500 Cells | % Survival 5000 Cells |
|--------------------------|-----------------------|-----------------------|
| Untreated                | 100                   | 100                   |
| 90 μM BBR                | 60.5                  | 51.3                  |
| 45 μM BBR                | 61.5                  | 45.4                  |
| 20 nM EPI                | 70.2                  | 61.8                  |
| 90 μM BBR + 20 nM EPI    | 55.2                  | 46.4                  |
| 45 μM BBR + 20 nM EPI    | 55.2                  | 46.4                  |

C.

| Total No. of Cells & %S | Vehicle Control | Berberine (45 μM) | Berberine (90 μM) | Epirubicin (20 nM) | Epirubicin (40 nM) | Berberine (90 μM) + Epirubicin (20 nM) | Berberine (90 μM) + Epirubicin (40 nM) | Berberine (45 μM) + Epirubicin (20 nM) | Berberine (45 μM) + Epirubicin (40 nM) |
|-------------------------|-----------------|-------------------|-------------------|-------------------|-------------------|----------------------------------------|----------------------------------------|----------------------------------------|----------------------------------------|
| 2500 & %S              | 100             | 90                | 28.95             | 4.74              | 3.16              | 1.05                                   | 1.05                                   | 1.05                                   | 1.05                                   |
| 5000 & %S              | 100             | 72.15             | 8.86              | 3.38              | 2.58              | 1.29                                   | 0.64                                   | 0                                       | 1.29                                   |
Figure 5 Clonogenic Assay on MDA MB 231 breast cancer cells after BBR & EPI treatment alone & in Combination. Berberine at different concentrations inhibits clonogenicity of MCF-7 cells as determined by clonogenic cell survival assay. A. Graphical representation for Inhibition of reproductive potential of MDA MB 231 cells after treatment as determined by Clonogenic assay. B. Tabulation of the % Survival after treatment with Berberine & Epirubicin alone and in combination. P.E: Plating Efficiency; % S: Percentage Survival

| Concentrations | % Survival 2500 cells plated | % Survival 5000 cells plated |
|----------------|-------------------------------|-------------------------------|
| untreated      |                               |                               |
| 10 µM BBR      |                               |                               |
| 20 µM BBR      |                               |                               |
| 150 nM EPI     |                               |                               |
| 500 nM EPI     |                               |                               |
| 10 µM          |                               |                               |
| 10 µM          |                               |                               |
| 20 µM          |                               |                               |
| 20 µM          |                               |                               |

| Vehicle Control | Berberine 10 µM | Berberine 20 µM | Epirubicin 150 nM | Epirubicin 300 nM |
|-----------------|----------------|----------------|------------------|------------------|
| Total No. of Cells & %S |                |                |                  |                  |
| 2500 & %S       | 100            | 23.03          | 19.1             | 26.97            | 22.47            | 15.17            | 16.29            | 15.73            | 11.80            |
| 5000 & %S       | 100            | 29.74          | 34.36            | 40.51            | 13.33            | 15.38            | 12.31            | 15.90            | 13.33            |
Figure 6 Berberine alone & in Combination with Epirubicin inhibits cell migration in A. MDA MB 231 & B. MCF-7 cells
**Figure 7** qPCR analysis of apoptotic markers in MDA MB 231 cells after treatment. qPCR analysis for (A) Bcl-2 (B) BAX (C) Caspase 3 (D) Caspase 9. GAPDH was used as internal control for normalization.
Figure 8 qPCR analysis of apoptotic markers in MCF-7 cells after treatment. qPCR analysis for (A) Bcl-2 GAPDH was used as internal control for normalization.

Figure 9 Western blot analysis of important marker proteins for Apoptosis in MDA-MB231 & MCF-7 cells exposed to Berberine. Actin was used as loading control.
Supplementary Figure 1 Growth inhibitory effects of Epirubicin (EPI) on breast cancer cells. Representative micrographs from random fields of view (magnification 20X) of indicated cells treated with and without Epirubicin.
Supplementary Figure 2 Growth inhibitory effects of Epirubicin (EPI) on breast cancer cells. Representative micrographs from random fields of view (magnification 20X) of indicated cells treated with and without Epirubicin.
Supplementary Figure 3: Anti-proliferative effects of Epirubicin on MDA MB 231 breast cancer cells

Supplementary Figure 4: Anti-proliferative effects of Epirubicin on MCF-7 breast cancer cells

Mammary carcinoma is the foremost cause of cancer-associated deaths among women worldwide (Surh, 2003). Great advances have been consummated in comprehending breast carcinogenesis and its progression. On the other hand, development of treatment for this cancer has been relatively slow and also affluent (Nobili et al., 2009). The objective to be achieved in breast cancer chemotherapy is to discern chemotherapeutic agents with extreme specificity, bioavailability, and nominal toxicity to normal tissues and organs. Several groups throughout the world have ventured on identifying lead drug molecules from natural resources that fulfill these needs (Saldanha et al., 2012). Thus photochemistry research has remained in the forefront of basic biomedical research in the recent years. Thus the present work essentially attempts to contribute meaningful outcomes in this arena.

Berberine is a natural dietary product which has shown promising cancer chemotherapeutic potential. It is an isoquinoline quaternary alkaloid present in the rhizome of numerous medicinal plants. Several mechanisms by which Berberine inhibits the proliferation of different cancer cell lines have been reported. Among them, the killing of cancer cells by the activation of apoptosis is the best characterized. In the present study Berberine alone and in combination with a widely used anti-cancer agent Epirubicin were analyzed for their effect on cell viability, induction of apoptosis, clonogenicity, and cell migration. Further to these cell biology assays, combination chemotherapy experiments using Berberine and Epirubicin were also carried out in three different settings to churn out a translational relevance for the study. The study envisaged to propose that Berberine can be used in combination with Epirubicin for treatment of Epirubicin 24 hr

Epirubicin 48 hr

Epirubicin 72 hr

Epirubicin concentration (% viability)

Epirubicin concentration (% viability)

Epirubicin concentration (% viability)

IC_{50} = 1.13 \mu M

IC_{50} = 85.2 nM

IC_{50} = 7.69 nM

R^2 = 0.97

R^2 = 0.94

R^2 = 0.88
breast cancers. Experimental studies using Berberine alone and in combination with Epirubicin have evidently shown the inhibition of cell growth on cultured breast cancer cells and the combination effects are synergistic, which is a novel finding.

Conclusion

This novel study showcased the synergistic effect of Berberine and Epirubicin in breast cancer cell lines MCF-7 and MDA MB-231. Berberine is known to induce apoptosis in cancer cells and the combination of the two drugs shows inhibition on cell growth and higher expression of apoptotic markers in-vitro. This preliminary study suggests that the combination of Berberine and Epirubicin can kill the cancer cells without harming the normal cells and further studies are required before bringing this combination into clinical practice.

References

1. Torres MP, Rachagani S, Purohit V, Pandey P, Joshi S, Moore ED, Johansson SL, Singh PK, Ganti AK, Batra SK. Graviola: A novel promising natural-derived drug that inhibits tumorigenicity and metastasis of pancreatic cancer cells in vitro and in vivo through altering cell metabolism. Cancer letters; 2012 Oct 1; 323(1): 29-40.

2. Malvia S, Bagadi SA, Dubey US, Saxena S. Epidemiology of breast cancer in Indian women. Asia Pac J Clin Oncol; 2017 Aug; 13(4): 289-295.

3. Allemani C, Matsuda T, Di Carlo V, Harewood R, Matz M, Nikšić M, Bonaventure A, Valkov M, Johnson CJ, Estève J, Ogunbiyi OJ. Global surveillance of trends in cancer survival 2000–14 (CONCORD-3): analysis of individual records for 37 513 025 patients diagnosed with one of 18 cancers from 322 population-based registries in 71 countries. The Lancet; 2018 Mar 17; 391(10125):1023-75.

4. Kim S, Lee J, You D, Jeong Y, Jeon M, Yu J, Kim SW, Nam SJ and Lee JE. (2018). Berberine suppresses cell motility through downregulation of TGF-β1 in triple negative breast cancer cells. Cellular Physiol Biochem; 45(2):795-807.

5. Tong N, Zhang J, Chen Y, Li Z, Luo Y, Zuo H, Zhao X. Berberine sensitizes multiple human cancer cells to the anticancer effects of doxorubicin in vitro. Oncolet Lett; 2012 Jun; 3(6):1263-1267.

6. Rafehi H, Orlowski C, Georgiadis GT, Ververis K, El-Osta A, Karagiannis TC. Clonogenic assay: adherent cell. J vis Exp. 2011;13(49): pii 2573.

7. Ahmadiankia, N., Moghaddam, H. K., Mishan, M. A., Bahrami, A. R., Naderi-Meshkin, H., Bidkhor, H. R., Mirfeyzi, S. J. A. (2016). Berberine suppresses migration of MCF-7 breast cancer cells through down-regulation of chemokine receptors. Iranian Journal of Basic Medical Sciences; 19(2), 125–131.

8. Chou TC. Theoretical basis, experimental design, and computerized simulation of synergism and antagonism in drug combination studies. Pharmacol Rev. 2006 Sep; 58(3):621-81.

9. Balakrishna, A., & Kumar, M. H. (2015). Evaluation of Synergetic Anticancer Activity of Berberine and Curcumin on Different Models of A549, Hep-G2, MCF-7, Jurkat, and K562 Cell Lines. BioMed Research International; 2015, 354614.

10. Patil JB, Kim J, Jayaprakasha GK. Berberine induces apoptosis in breast cancer cells (MCF-7) through mitochondrial-dependent pathway. Eur J Pharmacol; 2010 Oct 25; 645(1-3):70-8.

11. American cancer society. [Online]. 2011; Available from: URL: http://www.cancer.org/

12. Surh, Y., 2003. Cancer chemoprevention with dietary phytochemicals. Nat. Rev. Cancer 3; 768–780.

13. Nobili, S., Lippi, D., Witort, E., Donnini, M., Bausi, L., Mini, E., Capaccioli, S., 2009. Natural compounds for cancer treatment and prevention. Pharmacol. Res. 59; 365–378.

14. Saldanha SN, Tollefsbol TO. The role of nutraceuticals in chemoprevention and chemotherapy and their clinical outcomes. J Oncol; 2012: 1-23.

How to cite this article:

Prabhu Rathnam, K.S.V. and Damodara Reddy, C. 2018. In-vitro Anticancer Activity of Berberine alone and in Combination with Epirubicin on Breast Cancer Cells. Int.J.Curr.Res.Aca.Rev. 6(6), xx-xx.

doi: https://doi.org/10.20546/ijcrrar.2018.606.xxx